These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 9268188)
21. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Nutescu EA; Spinler SA; Wittkowsky A; Dager WE Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109 [TBL] [Abstract][Full Text] [Related]
22. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Frank RD; Brandenburg VM; Lanzmich R; Floege J Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159 [TBL] [Abstract][Full Text] [Related]
23. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504 [TBL] [Abstract][Full Text] [Related]
24. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin. Peternel P; Terbizan M; Tratar G; Bozic M; Horvat D; Salobir B; Stegnar M Thromb Res; 2002 Feb; 105(3):241-6. PubMed ID: 11927130 [TBL] [Abstract][Full Text] [Related]
25. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
27. In vitro anticoagulation monitoring of low-molecular-weight heparin. Wang JQ; Shi XB; Yang JG; Hu DY Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471 [TBL] [Abstract][Full Text] [Related]
28. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. Naumnik B; Pawlak K; Myśliwiec M Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290 [TBL] [Abstract][Full Text] [Related]
29. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Haas S; Wolf H; Kakkar AK; Fareed J; Encke A Thromb Haemost; 2005 Oct; 94(4):814-9. PubMed ID: 16270636 [TBL] [Abstract][Full Text] [Related]
30. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. Cavusoglu E; Lakhani M; Marmur JD J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447 [TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Sifil A; Mermut C; Yenicerioglu Y; Cavdar C; Gumustekin M; Celik A; Yuksel F; Camsari T Adv Perit Dial; 2003; 19():28-30. PubMed ID: 14763030 [TBL] [Abstract][Full Text] [Related]
32. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357 [TBL] [Abstract][Full Text] [Related]
33. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668 [TBL] [Abstract][Full Text] [Related]
35. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258 [TBL] [Abstract][Full Text] [Related]
36. Therapy of unstable angina with the low molecular weight heparins. Ageno W; Turpie AG Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233 [TBL] [Abstract][Full Text] [Related]
37. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277 [TBL] [Abstract][Full Text] [Related]
38. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Alban S; Gastpar R Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675 [TBL] [Abstract][Full Text] [Related]
39. Dalteparin: new indication. Prophylaxis in medical patients: no advance. Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. Krieter DH; Fink S; Dorsch O; Harenberg J; Melzer N; Wanner C; Lemke HD Artif Organs; 2015 Nov; 39(11):951-9. PubMed ID: 25900127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]